Fundraising FoxKaryopharm Therapeutics
Newton, US · Founded 2008 · 4 known investors
Find your way into Karyopharm Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Deepa Pakianathan to introduce you to Richard Paulson
You →Deepa · together at Karyopharm Therapeutics Inc. →Richard
Ask Jamie Chen to introduce you to Stuart Poulton
You →Jamie · together at Karyopharm Therapeutics Inc. →Stuart
Ask Sam Okafor to introduce you to Reshma Rangwala
You →Sam · together at Aravive, Inc. →Reshma
Sign up to find every way you can get introduced to Karyopharm Therapeutics
- Your email: who you already know at Karyopharm Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Karyopharm Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
Founders & leadership
Board
Investors · 4
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: HEALTHCARE ROYALTY PARTNERS's portfolio page · Not right? Tell us
How we know: investing.com · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$165M disclosed across 1 of 2 rounds · 2022–2026
- Undisclosed amountprivate placementMar 2026Source ↗
▶$165MraisedDec 2022 · 33 investors · PharmaceuticalsRule 506(b)
- Peter HonigDirector
- Barry E. GreeneDirector
- Stuart PoultonExecutive Officer
- Michael ManoExecutive Officer
- Reshma RangwalaExecutive Officer
- Richard PaulsonExecutive Officer, Director
- Deepika R. PakianathanDirector
- Chen SchorDirector
- Stephen MitchenerExecutive Officer
- Michael MasonExecutive Officer
- Mansoor Raza MirzaDirector
- Garen G. BohlinDirector
- Christy J. OligerDirector
- Sohanya ChengExecutive Officer
- Offering amount
- $165M
- Amount sold
- $165M
- Sales commissions
- $9.9M
- Placement agents
- Robert W. Baird & Co. Incorporated, Piper Sandler & Co., Jefferies LLC, Barclays Capital, Inc., H.C. Wainwright & Co. LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Karyopharm Therapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Karyopharm Therapeutics do?
- Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
- Who are Karyopharm Therapeutics's investors?
- Karyopharm Therapeutics's investors include Avoro Capital Advisors, Foresite Capital, HEALTHCARE ROYALTY PARTNERS, RA Capital.
- How much funding has Karyopharm Therapeutics raised?
- Karyopharm Therapeutics has disclosed $165M raised across 1 of its 2 known rounds.
- Where is Karyopharm Therapeutics headquartered?
- Karyopharm Therapeutics is headquartered in Newton, US.